Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (8830)	7/15/2003 6:08:24 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 52153

INGN is also busy reporting on science behind 241. Press Release Source: Introgen Therapeutics, Inc. Study Suggests Promising Prostate Cancer Treatment With Introgen's INGN 241 Anti-Cancer Drug Tuesday July 15, 1:08 pm ET Cell Killing is Selective for Prostate Cancer, Normal Prostate Cells Unharmed AUSTIN, Texas, July 15 /PRNewswire-FirstCall/ -- Introgen Therapeutics, Inc. (Nasdaq: INGN - News) announced the publication of preclinical research which suggests INGN 241, its mda-7 therapeutic, exhibits tumor selectivity in prostate cancer cells, was not toxic to normal cells and may be a possible treatment for prostate cancer. The study results were previously published in the 2003 Proceedings Online of the American Association for Cancer Research (AACR) and have been published in the 2nd edition of the 2003 proceedings of the AACR. INGN 241 is currently undergoing phase 1 and phase 2 clinical testing for multiple tumor types. "The information we have gathered about INGN 241 and its ability to almost universally kill cancer cells without harming normal cells could accelerate Introgen's development of INGN 241 as a possible treatment for prostate cancer," said Sunil Chada, Ph.D., Introgen's director of research and development. In the study, abstract #1078, Introgen, and its collaborators at M. D. Anderson Cancer Center investigated the anti-tumor activity of INGN 241 and the underlying mechanisms of action in prostate cancer cells, and normal prostate epithelial cells. Cells treated with INGN 241 express high levels of MDA-7 protein which induce significant suppression of cell growth and cell death in the prostate cancer cells, but not in the normal prostate cells. The study results indicate the methods by which the tumor killing occurs include the activation of certain molecular pathways, inhibiting others, and induces cell cycle arrest. Cell death, or apoptosis, is induced by INGN 241 in tumor cells even if the p53 gene, implicated in one half of all cancers, is mutated, suggesting broad applicability. The scientists concluded the cancer cell killing ability of INGN 241 is tumor selective, and importantly, that there is no toxicity associated with the drug to normal cells. According to the American Cancer Society, an estimated 220,000 new cases of prostate cancer will occur in the U.S. this year, with an estimated 29,000 deaths. Prostate cancer is the second leading cause of cancer death in men.